Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients

被引：2

作者：

Ferrucci, Silvia ^{[1
]}

Tavecchio, Simona ^{[1
]}

Maronese, Carlo Alberto ^{[1
,2
]}

Balato, Anna

Di Brizzi, Eugenia Veronica ^{[3
]}

Ortoncelli, Michela ^{[4
]}

Ribero, Simone ^{[4
]}

Girolomoni, Giampiero ^{[5
]}

Maurelli, Martina ^{[5
]}

Fortina, Anna Belloni ^{[6
]}

Caroppo, Francesca ^{[6
]}

Naldi, Luigi ^{[7
,8
]}

Pezzolo, Elena ^{[8
]}

Nettis, Eustachio ^{[9
]}

Pugliese, Francesco ^{[9
]}

Stingeni, Luca ^{[10
]}

Hansel, Katharina ^{[10
]}

Rubegni, Giovanni ^{[11
]}

Calabrese, Laura ^{[12
]}

Russo, Filomena ^{[13
]}

Gola, Massimo ^{[14
]}

Magnaterra, Elisabetta ^{[14
]}

Rongioletti, Franco ^{[15
]}

Mercuri, Santo Raffaele ^{[15
]}

Paolino, Giovanni ^{[15
]}

Savoia, Paola ^{[16
,17
]}

Veronese, Federica ^{[17
]}

Foti, Caterina ^{[18
]}

Ambrogio, Francesca ^{[19
]}

Scalvenzi, Massimiliano ^{[20
]}

Napolitano, Maddalena

Patruno, Cataldo ^{[21
]}

Dastoli, Stefano ^{[21
]}

Corazza, Monica ^{[22
]}

Borghi, Alessandro ^{[22
]}

Calzavara-Pinton, Pier Giacomo ^{[23
]}

Rossi, Mariateresa ^{[23
]}

Offidani, Annamaria ^{[24
]}

Radi, Giulia ^{[24
]}

Bonzano, Laura ^{[25
]}

Ferreli, Caterina ^{[26
]}

Piras, Viviana ^{[26
]}

Satta, Rosanna ^{[27
]}

Sucato, Federica ^{[27
]}

Malagoli, Piergiorgio ^{[28
]}

Gaiani, Francesca ^{[28
]}

Micali, Giuseppe ^{[29
]}

Musumeci, Maria Letizia ^{[29
]}

Fargnoli, Maria Concetta ^{[30
]}

Esposito, Maria ^{[31
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[3] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy

[4] Univ Turin, Med Sci Dept, Dermatol Clin, Turin, Italy

[5] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy

[6] Univ Padua, Dept Women & Children Hlth, Padua, Italy

[7] Italian Grp Epidemiol Res Dermatol, Study Ctr, Bergamo, Italy

[8] San Bortolo Hosp Vicenza, Dept Dermatol, Vicenza, Italy

[9] Univ Bari, Sch & Chair Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Bari, Italy

[10] Univ Perugia, Dept Med, Sect Dermatol, Perugia, Italy

[11] Univ Siena, Dept Ophthalmol, Siena, Italy

[12] Univ Siena, Dept Med Sci Surg & Neurosci, Sect Dermatol, Siena, Italy

[13] IDI IRCCS, Ist Dermopat Immacolata, Rome, Italy

[14] Azienda Sanit & Univ Florence, Piero Palagi Hosp, Sect Dermatol, Viale Michelangiolo, Florence, Italy

[15] IRCCS San Raffaele Hosp, Dermatol Clin, Milan, Italy

[16] Univ Piemonte Orientale, Dept Hlth Sci, Novara, Italy

[17] AOU Maggiore della Carita Novara, Novara, Italy

[18] Univ Bari, Dept Dermatol, Dipartimento Sci Biomed & Oncol Umana, Bari, Puglia, Italy

[19] Univ Bari, Dept Precis & Regenerat Med & Ionian Area DiMePRe, Sect Dermatol & Venereol, Bari, Italy

[20] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[21] Magna Graecia Univ Catanzaro, Catanzaro, Calabria, Italy

[22] Univ Ferrara, Dept Med Sci, Sect Dermatol, Ferrara, Emilia Romagna, Italy

[23] Univ Brescia, Dermatol Dept, Brescia, Italy

[24] Univ Politecn Marche, Dept Clin & Surg Specialties, Fac Med & Chirurg, Ancona, Marche, Italy

[25] AUSL Modena, Allergol Serv, Modena, Italy

[26] Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy

[27] Univ Sassari, Dept Med Surg & Expt Sci, Dermatol Unit, Sassari, Italy

[28] Ist Policlin San Donato, Milan, Italy

[29] Univ Catania, Catania, Italy

[30] Univ Aquila, Dept Dermatol, Laquila, Italy

[31] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[32] Univ Rome Sapienza, Dermatol Unit, Rome, Italy

[33] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2024年 / 49卷 / 12期

关键词：

EUROPEAN GUIDELINES; ADULTS; MANAGEMENT; PLACEBO;

D O I：

10.1093/ced/llae208

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long-term treatment outcomes is currently available to inform clinical decisions. Objectives To describe the long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD. Methods A multicentre, retrospective, dynamic cohort study was conducted to assess long-term effectiveness and safety of dupilumab in patients with moderate-to-severe AD in a real-world setting. Predictors of minimal disease activity (MDA) optimal treatment target criteria [defined as the simultaneous achievement of a 90% reduction in Eczema Area and Severity Index score, itch-numeric rating scale (NRS) score <= 1, sleep-NRS score <= 1 and Dermatology Life Quality Index <= 1] were investigated. Results In total, 2576 patients were enrolled from June 2018 to July 2022. MDA optimal treatment target criteria were achieved by 506/2309 (21.9%), 769/1959 (39.3%), 628/1247 (50.4%), 330/596 (55.4%) and 58/106 (54.7%) of those that reached 4, 12, 24, 36 and 48 months of follow-up, respectively. Logistic regression revealed a negative effect on MDA achievement for conjunctivitis and food allergy at all timepoints. Adverse events (AEs) were mild and were observed in 373/2364 (15.8%), 166/2066 (8.0%), 83/1291 (6.4%), 27/601 (4.5%) and 5/110 (4.5%) of those that reached 4, 12, 24, 36 and 48 months of follow-up. Conjunctivitis was the most frequently reported AE during the available follow-up. AEs led to treatment discontinuation in < 1% of patients during the evaluated time periods. Conclusions The high long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate-to-severe AD, regardless of clinical phenotype and course (persisting or relapsing) at baseline. Further research will be needed to investigate the effect of T helper cell 2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD.

引用

页码：1561 / 1572

页数：12

共 50 条

[1] Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience
Stingeni, L.
Bianchi, L.
Antonelli, E.
Caroppo, E. S.
Ferrucci, S. M.
Ortoncelli, M.
Fabbrocini, G.
Nettis, E.
Schena, D.
Napolitano, M.
Gola, M.
Bonzano, L.
Rossi, M.
Fortina, A. Belloni
Balato, A.
Peris, K.
Foti, C.
Guarneri, F.
Romanelli, M.
Patruno, C.
Savoia, P.
Fargnoli, M. C.
Russo, F.
Errichetti, E.
Bianchelli, T.
Bianchi, L.
Pellacani, G.
Feliciani, C.
Offidani, A.
Corazza, M.
Micali, G.
Milanesi, N.
Malara, G.
Chiricozzi, A.
Tramontana, M.
Hansel, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1292 - 1299
[2] Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China
Wang, Yuyi
Jia, Ruiling
Hu, Qin
Tao, Xiao
He, Qi
Luo, Guangying
Xiong, Qiong
Zhang, Zhongyu
Xiao, Yujuan
Liu, Yi
FRONTIERS IN IMMUNOLOGY, 2024, 15
[3] Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis
Kim, Nicole S.
Maliyar, Khalad
Oliveira, Luciana
O'Toole, Ashley
Gooderham, Melinda J.
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2020, 59 (10) : E361 - E363
[4] Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study
Pezzolo, Elena
Rossi, MariaTeresa
Caroppo, Francesca
Bianchelli, Tommaso
Fortina, Anna Belloni
Giacchetti, Alfredo
Pinton, Piergiacomo Calzavara
Naldi, Luigi
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (06) : E757 - E759
[5] Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study
Yang, Chin-Yi
Lai, Po-Ju
Chen, Chun-Bing
Chan, Tom C.
Hui, Rosaline Chung-Yee
Huang, Yu-Huei
Tseng, Han-Chi
Lin, Shang-Hung
Lu, Chun-Wei
Lee, Hua-En
Lin, Jing-Yi
Chi, Min-Hui
Tsai, Ming-Feng
Hwang, Yih-Shiou
Wang, Chuang-Wei
Chu, Chia-Yu
Chung, Wen-Hung
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
[6] Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study
Yang, Dan-Yang
Li, Li
Lu, Tao
Jing, Wen-Wen
Liu, Xin
Li, Xiao-Li
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (03) : 467 - 472
[7] Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study
Dan-Yang Yang
Li Li
Tao Lu
Wen-Wen Jing
Xin Liu
Xiao-Li Li
Archives of Dermatological Research, 2023, 315 : 467 - 472
[8] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
Deleuran, M.
Thaci, D.
Beck, L.
Forman, S.
Soong, W.
Hussain, I.
Bissonnette, R.
Bouaziz, J.
Gelfand, J.
Lawrence, S.
Chen, Z.
Akinlade, B.
Gadkari, A.
Eckert, L.
Graham, N.
Ardeleanu, M.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
[9] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Deleuran, Mette
Thaci, Diamant
Beck, Lisa A.
Forman, Seth
Soong, Weily
Hussain, Iftikhar
Bissonnette, Robert
Bouaziz, Jean-David
Gelfand, Joel
Sher, Lawrence
Chen, Zhen
Akinlade, Bolanle
Gadkari, Abhijit
Eckert, Laurent
Graham, Neil M. H.
Pirozzi, Gianluca
Ardeleanu, Marius
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
[10] Real-world experience of dupilumab for patients with moderate-to-severe atopic dermatitis in a tertiary care setting
Kreeshan, F. C.
Lavery, D.
Clarke, S.
Warren, R. B.
Hunter, H. J. A.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 70 - 70

← 1 2 3 4 5 →